Translational medicine

Sanofi is convinced by what translational medicine has brought to the field. “Every day, we work internally and externally to strengthen cooperation between all the researchers whose work is focused on patients,” explains Dr. Elias Zerhouni, President Global R&D at Sanofi. “This new discipline, which we hope to integrate into all our R&D methods, will be a major tool for accomplishing our mission, especially when backed by open innovation.”
For example, in the field of familial hypercholesterolemia, the PCSK9 antibody that Sanofi is developing in partnership with Regeneron is scheduled to enter into Phase III trials on the heels of encouraging efficacy studies done in 2011. The discovery of the antibody’s target, the PCSK9 protein, was the result of a remarkable translational study in humans.

Read more